Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| European Union H2020 SME Instrument | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of the study is to demonstrate the non-inferiority of the personalized Neurofeedback Training device versus Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder.
The main objective of the present study is to demonstrate the non-inferiority of the personalized Neurofeedback Training device ADHD@Home versus Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder.
Furthermore, it is aimed to learn more about the mechanisms underlying NeuroFeedback.
The study is prospective, multicentric (9 centres), randomised, reference drug-controlled.
ADHD@Home is a neuromarkerTM-based personalized medicine device to treat children suffering from Attention Deficit Hyperactivity Disorders (ADHD) with Neurofeedback Training (NFT) based on real time electroencephalography (EEG) signal.
Neurofeedback Training is based on direct training of brain function, by which the brain learns to function more efficiently. For each session of the ADHD@Home solution, the child is trained to modulate his brain activity in a serious game, which is a real-time metaphor of the EEG biomarker that needs to be 'normalized', following a typical operant learning process.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neurofeedback NFT | Experimental | Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game. Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home |
|
| Methylphenidate MPH | Active Comparator | Methylphenidate long acting preparation. Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day). Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neurofeedback NFT | Device | The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier. The training is personalized according to patient's characteristics. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Day 0 at Day 90 of the total score of the ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV) | ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): total score assessed by the clinician | 3 times (Day 0, Day 60, Day 90) |
| Measure | Description | Time Frame |
|---|---|---|
| ADHD RS IV Inattention and Hyperactivity Sub-Scores | ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Inattention and Hyperactivity sub-scores assessed by the clinician | 3 times (Day 0, Day 60, Day 90) |
| Clinical responders |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michel Du Peloux, PhD | Contact | 062-434-1061 | +33 | michel.du-peloux@mensiatech.com |
| Name | Affiliation | Role |
|---|---|---|
| Michel Du Peloux, PhD | Mensia Technologies | Study Director |
| Diane Purper-Ouakil, MD/PhD | CHRU Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| PSY Pluriel Centre europeen de psychologie medicale | Recruiting | Brussels | 1080 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34165190 | Derived | Purper-Ouakil D, Blasco-Fontecilla H, Ros T, Acquaviva E, Banaschewski T, Baumeister S, Bousquet E, Bussalb A, Delhaye M, Delorme R, Drechsler R, Goujon A, Hage A, Kaiser A, Mayaud L, Mechler K, Menache C, Revol O, Tagwerker F, Walitza S, Werling AM, Bioulac S, Brandeis D. Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial. J Child Psychol Psychiatry. 2022 Feb;63(2):187-198. doi: 10.1111/jcpp.13462. Epub 2021 Jun 24. | |
| 31370811 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Methylphenidate MPH | Drug | Drug prescribed with a first titration period until an optimal dose. |
|
|
Clinical responders are subjects who will present a decrease of the total clinician ADHD RS score of more or equal to 25%
| 1 time (Day 90) |
| Parents ADHD RS IV Total, Inattention and Hyperactivity Scores | ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Total, Inattention and Hyperactivity scores assessed by the parents | 3 times (Day 0, Day 60, Day 90) |
| Teacher ADHD RS IV Total, Inattention and Hyperactivity Scores | ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Total, Inattention and Hyperactivity scores assessed by the teacher | 2 times (Day 0, Day 90) |
| Clinical Global Impression (severity) (CGI-S) | Severity of the illness assessed by the clinician | 7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Clinical Global Impression (improvement) (CGI-I) | Improvement of the patient's condition assessed by the clinician | 6 times (Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Behavior Rating Inventory of Executive Function (BRIEF) | Executive Function Tests by the Behavior Rating Inventory of Executive Function (BRIEF) | 2 times (Day 0, Day 90) |
| Conners Continuous Performance Test 3rd Edition (Conners CPT 3) | Conners Continuous Performance Test 3rd Edition | 2 times (Day 0, Day 90) |
| Strengths and Difficulties Questionnaire (SDQ) | Behaviour assessment by the parents and the teacher with the Strengths and Difficulties Questionnaire | 2 times (Day 0, Day 90) |
| quantitative Electro-Encephalogram (qEEG) | Quantitative electroencephalogram to assess EEG biomarkers, progress in brain modulation | 3 times (Day 0, Day 60, Day 90) |
| Columbia suicide severity rating scale (C-SSRS) | Columbia suicide severity rating scale | 7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Sleep Disturbance Scale for Children (SDSC) | Sleep Disturbance Scale for Children | 7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Pediatric adverse event rating scale (PAERS) | Pediatric adverse event rating scale | 7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Physical examination | Physical examination will include assessments of height, weight, cardiac frequency, cardiac exam and blood pressure. Investigator will question the parents about the cardiac history of the family and on individual risk factors. If a risk factor is detected, the patient will be addressed to a cardiologist for an electrocardiogram (ECG). | 1 time (Day 0) |
| Medical/surgical history | Assessment especially related to the eligibility criteria | 1 time (Day 0) |
| Concomitant treatments collection | All the treatments taken during the participation will be collected (trade name, indication, dose, onset/end dates). The use of concomitant medications will be summarized by therapeutic class. | 7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Adverse events collection | All the adverse events occurred during the participation will be collected until resolution or stabilization (description/symptoms, onset/end dates, frequency, intensity, evolution, causality to treatment attributed, seriousness). All adverse events will be described in each arm. A comparison will be done, especially concerning number and percentage of patients who experienced at least one adverse event (on the whole and by system/organ), at least one adverse event leading to discontinue the treatment, and at least one serious adverse event. | 6 times (Day 7, Day 14, Day 21, Day 28, Day 60, Day 90) |
| Child Health and Illness Profile, Child Edition (CHIP-CE) | Measure of the quality of life by the parents with the CHIP-CE parents report form | 2 times (Day 0, Day 90) |
| Hôpital Erasme - Cliniques universitaires de Bruxelles | Not yet recruiting | Brussels | B-1070 | Belgium |
|
| Centre Hospitalier Charles Perrens | Recruiting | Bordeaux | 33076 | France |
|
| CHRU de Lille - Hôpital Fontan - Service de psychiatrie de l'enfant et de l'adolescent | Recruiting | Lille | 59000 | France |
|
| Clinique LAUTREAMONT | Recruiting | Lille | 59120 | France |
|
| Hospice Civil de Lyon - Hôpital Neurologique Service de Neuro-Psychiatrie de l'Enfant | Recruiting | Lyon | 59003 | France |
|
| CHRU Montpellier | Recruiting | Montpellier | 34000 | France |
|
| Universitätklinikum Erlangen | Terminated | Erlangen | Bavaria | 91052 | Germany |
| Medical faculty of Mannheim/Heidelberg university | Not yet recruiting | Mannheim | 68159 | Germany |
|
| Puerta de Hierro Hospital - Department of Psychiatry | Recruiting | Madrid | 28400 | Spain |
|
| Clinique des Grangettes | Not yet recruiting | Geneva | 1206 | Switzerland |
|
| Psychiatric Hospital, University of Zürich | Not yet recruiting | Zurich | CH- 8032 | Switzerland |
|
| Derived |
| Bioulac S, Purper-Ouakil D, Ros T, Blasco-Fontecilla H, Prats M, Mayaud L, Brandeis D. Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD. BMC Psychiatry. 2019 Aug 1;19(1):237. doi: 10.1186/s12888-019-2218-0. |
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D008774 | Methylphenidate |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided